Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NeuroSense Therapeutics Ltd. before investing.

In this article, we go over a few key elements for understanding NeuroSense Therapeutics Ltd.’s stock price such as:

• NeuroSense Therapeutics Ltd.’s current stock price and volume
• Why NeuroSense Therapeutics Ltd.’s stock price changed recently
• Upgrades and downgrades for NRSN from analysts
• NRSN’s stock price momentum as measured by its relative strength

About NeuroSense Therapeutics Ltd. (NRSN)

Before we jump into NeuroSense Therapeutics Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Want to learn more about NeuroSense Therapeutics Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NeuroSense Therapeutics Ltd..

NeuroSense Therapeutics Ltd.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, NeuroSense Therapeutics Ltd.’s stock price was $0.511.

NeuroSense Therapeutics Ltd. is up 27.19% from its previous closing price of $0.402.

During the last market session, NeuroSense Therapeutics Ltd.’s stock traded between $0.360 and $0.530. Currently, there are approximately 25.56 million shares outstanding for NeuroSense Therapeutics Ltd..

NeuroSense Therapeutics Ltd.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

NeuroSense Therapeutics Ltd. Stock Price History

NeuroSense Therapeutics Ltd.’s (NRSN) price is currently up 19.71% so far this month.

During the month of September, NeuroSense Therapeutics Ltd.’s stock price has reached a high of $0.530 and a low of $0.360.

Over the last year, NeuroSense Therapeutics Ltd. has hit prices as high as $1.980 and as low as $0.250. Year to date, NeuroSense Therapeutics Ltd.’s stock is down 33.58%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused NeuroSense Therapeutics Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were analysts who downgraded NeuroSense Therapeutics Ltd.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate NeuroSense Therapeutics Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NeuroSense Therapeutics Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NeuroSense Therapeutics Ltd. (NRSN) by visiting AAII Stock Evaluator.

Relative Price Strength of NeuroSense Therapeutics Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, NeuroSense Therapeutics Ltd. has a weighted four-quarter relative price strength of -24.10%, which translates to a Momentum Score of 9 and is considered to be Very Weak.

Want to learn more about how NeuroSense Therapeutics Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

NeuroSense Therapeutics Ltd. Stock Price: Bottom Line

As of September 4, 2026, NeuroSense Therapeutics Ltd.’s stock price is $0.511, which is up 27.19% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NeuroSense Therapeutics Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.